Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina generates revenue from two segments - Product and Service. Product are primarily attributed to the partnerships and collaborations to develop distributable clinical in-vitro diagnostics for Illumina sequencers. Service include genotyping and sequencing services as well as instrument maintenance contracts.
| Revenue (Most Recent Fiscal Year) | $4.50B |
| Net Income (Most Recent Fiscal Year) | $-1.16B |
| PE Ratio (Current Year Earnings Estimate) | 128.87 |
| PE Ratio (Trailing 12 Months) | 134.98 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.15 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.25 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 32.77 |
| Pre-Tax Margin (Trailing 12 Months) | -24.80% |
| Net Margin (Trailing 12 Months) | -25.78% |
| Return on Equity (Trailing 12 Months) | 2.20% |
| Return on Assets (Trailing 12 Months) | 1.25% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.66 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.29 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.26 |
| Inventory Turnover (Trailing 12 Months) | 2.93 |
| Book Value per Share (Most Recent Fiscal Quarter) | $36.18 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.14 |
| Earnings per Share (Most Recent Fiscal Year) | $0.86 |
| Diluted Earnings per Share (Trailing 12 Months) | $-7.34 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 159.26M |
| Free Float | 158.98M |
| Market Capitalization | $18.70B |
| Average Volume (Last 20 Days) | 1.43M |
| Beta (Past 60 Months) | 1.19 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.17% |
| Percentage Held By Institutions (Latest 13F Reports) | 89.42% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |